Radhakrishnan Pillai

1.5k total citations
56 papers, 1.1k citations indexed

About

Radhakrishnan Pillai is a scholar working on Dermatology, Epidemiology and Immunology. According to data from OpenAlex, Radhakrishnan Pillai has authored 56 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Dermatology, 19 papers in Epidemiology and 17 papers in Immunology. Recurrent topics in Radhakrishnan Pillai's work include Nail Diseases and Treatments (19 papers), Psoriasis: Treatment and Pathogenesis (17 papers) and Acne and Rosacea Treatments and Effects (15 papers). Radhakrishnan Pillai is often cited by papers focused on Nail Diseases and Treatments (19 papers), Psoriasis: Treatment and Pathogenesis (17 papers) and Acne and Rosacea Treatments and Effects (15 papers). Radhakrishnan Pillai collaborates with scholars based in United States, Japan and Canada. Radhakrishnan Pillai's co-authors include Yoshiyuki Tatsumi, Hisato Senda, David M. Pariser, Jason T. Olin, Boni E. Elewski, Mark Lebwohl, Richard Pollak, Eric Guenin, Kathleen Smith and Robert J. Israel and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Journal of the American Academy of Dermatology and Regulatory Toxicology and Pharmacology.

In The Last Decade

Radhakrishnan Pillai

56 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Radhakrishnan Pillai United States	20	593	505	398	224	76	56	1.1k
Urbà González United Kingdom	12	324 0.5×	353 0.7×	173 0.4×	109 0.5×	103 1.4×	23	935
Saeedeh Farajzadeh Iran	14	60 0.1×	159 0.3×	162 0.4×	69 0.3×	37 0.5×	48	493
Kıymet Baz Türkiye	12	89 0.2×	47 0.1×	357 0.9×	138 0.6×	84 1.1×	27	688
Jonathan S. Weiss United States	11	43 0.1×	218 0.4×	574 1.4×	47 0.2×	165 2.2×	17	712
Sandra Lorenzi Italy	10	397 0.7×	280 0.6×	106 0.3×	20 0.1×	23 0.3×	30	555
Deanne Daigle Canada	13	388 0.7×	261 0.5×	94 0.2×	19 0.1×	26 0.3×	24	507
E. YOUNG Netherlands	13	80 0.1×	38 0.1×	436 1.1×	242 1.1×	50 0.7×	29	696
Emily Harrell United States	12	209 0.4×	65 0.1×	39 0.1×	47 0.2×	61 0.8×	24	388
Enver Turan Türkiye	13	73 0.1×	35 0.1×	114 0.3×	86 0.4×	38 0.5×	46	402
Panjit Chieosilapatham Thailand	11	36 0.1×	16 0.0×	292 0.7×	137 0.6×	97 1.3×	15	546

Countries citing papers authored by Radhakrishnan Pillai

Since Specialization

Citations

This map shows the geographic impact of Radhakrishnan Pillai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Radhakrishnan Pillai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Radhakrishnan Pillai more than expected).

Fields of papers citing papers by Radhakrishnan Pillai

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Radhakrishnan Pillai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Radhakrishnan Pillai. The network helps show where Radhakrishnan Pillai may publish in the future.

Co-authorship network of co-authors of Radhakrishnan Pillai

This figure shows the co-authorship network connecting the top 25 collaborators of Radhakrishnan Pillai. A scholar is included among the top collaborators of Radhakrishnan Pillai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Radhakrishnan Pillai. Radhakrishnan Pillai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Draelos, Zoé Kececioglu, Leon Kircik, Joshua Zeichner, et al.. (2024). The Right Formula for Acne: Importance of Vehicle Formulation in Tazarotene 0.045% Lotion Design, Application, Tolerability, and Efficacy. Dermatologic Therapy. 2024(1). 1 indexed citations

Gold, Linda Stein, Hilary Baldwin, Leon Kircik, et al.. (2021). Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug. American Journal of Clinical Dermatology. 23(1). 93–104. 25 indexed citations

Tyring, Stephen K., Leon Kircik, David M. Pariser, et al.. (2020). The Effects of Once-Daily Tretinoin 0.05% Lotion on Quality of Life in Patients with Moderate-to-Severe Acne Vulgaris. American Journal of Clinical Dermatology. 21(6). 891–899. 1 indexed citations

Eichenfield, Lawrence F., Boni E. Elewski, Jeremy Sugarman, et al.. (2020). Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for Onychomycosis Treatment in Pediatric Patients. Journal of Drugs in Dermatology. 19(9). 867–872. 9 indexed citations

Eichenfield, Lawrence F., Boni E. Elewski, Jeremy Sugarman, et al.. (2020). Efinaconazole 10% topical solution for the treatment of onychomycosis in pediatric patients: Open-label phase 4 study. Journal of the American Academy of Dermatology. 84(4). 1140–1142. 11 indexed citations

Tanghetti, Emil, Leon Kircik, Lawrence J. Green, et al.. (2019). A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris. PubMed. 18(6). 542–542. 20 indexed citations

Kircik, Leon, et al.. (2019). Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis. PubMed. 18(3). 279–284.. 3 indexed citations

Blauvelt, Andrew, Lawrence J. Green, Mark Lebwohl, et al.. (2019). Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis. PubMed. 18(3). 297–299. 3 indexed citations

Lebwohl, Mark, Andrew Blauvelt, Alan Menter, et al.. (2019). Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study. American Journal of Clinical Dermatology. 20(6). 863–871. 30 indexed citations

10.

Green, Lawrence J., Francisco A. Kerdel, Fran Cook-Bolden, et al.. (2018). Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.. PubMed. 17(10). 1062–1069. 4 indexed citations

11.

Gold, Linda Stein, et al.. (2018). Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis. PubMed. 17(12). 1290–1296. 3 indexed citations

12.

Gold, Linda Stein, Leon Kircik, David M. Pariser, et al.. (2018). Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.. PubMed. 17(8). 863–868. 3 indexed citations

13.

Gold, Linda Stein, Mark Lebwohl, Jeremy Sugarman, et al.. (2018). Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials. Journal of the American Academy of Dermatology. 79(2). 287–293. 32 indexed citations

14.

Sugarman, Jeremy, et al.. (2017). A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.. PubMed. 16(3). 197–204. 19 indexed citations

15.

Lebwohl, Mark, Kim Papp, Lauren B. Marangell, et al.. (2017). Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. Journal of the American Academy of Dermatology. 78(1). 81–89.e5. 124 indexed citations

16.

Joseph, Warren S., Tracey C. Vlahovic, Radhakrishnan Pillai, & Jason T. Olin. (2014). Efinaconazole 10% Solution in the Treatment of Onychomycosis of the Toenails. Journal of the American Podiatric Medical Association. 104(5). 479–485. 1 indexed citations

17.

Sanada, Hisakazu, et al.. (2014). Nonclinical safety assessment of Efinaconazole Solution (10%) for onychomycosis treatment. Regulatory Toxicology and Pharmacology. 70(1). 242–253. 8 indexed citations

18.

Elewski, Boni E., Phoebe Rich, Richard Pollak, et al.. (2012). Efinaconazole 10% solution in the treatment of toenail onychomycosis: Two phase III multicenter, randomized, double-blind studies. Journal of the American Academy of Dermatology. 68(4). 600–608. 167 indexed citations

19.

Bikowski, Joseph, Radhakrishnan Pillai, & Braham Shroot. (2006). The position not the presence of the halogen in corticosteroids influences potency and side effects.. PubMed. 5(2). 125–30. 29 indexed citations

20.

Pillai, Radhakrishnan, et al.. (2001). Release of Hydrocortisone from a Cream Matrix: Dependency of Release on Suspension Concentration and Measurement of Solubility and Diffusivity. Pharmaceutical Development and Technology. 6(3). 373–384. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact